
BCAX
Bicara Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BCAX
Bicara Therapeutics Inc.
A clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors
116 Huntington Avenue, Suite 703, Boston, MA 02116
--
Bicara Therapeutics Inc., was incorporated in Delaware on December 12, 2018. They are a clinical-stage biopharmaceutical company dedicated to bringing transformative bifunctional therapies to patients with solid tumors. Their main project, Alpha, is a bifunctional antibody that combines two clinically validated targets, epidermal growth factor receptor (EGFR) -directed monoclonal antibodies and a domain that binds human transforming growth factor β (TGF-b). Through this dual targeting mechanism, Alfa has the potential to exert powerful anti-tumor activity by simultaneously blocking the survival and proliferation of EGFR inherent in cancer cells, as well as immunosuppressive TGF-b signaling in the tumor microenvironment (TME). Ficerafusp alfa introduces TGF-b inhibitors directly into TME by binding to EGFR on tumor cells, which they believe will lead to a durable response and an increase in overall survival or OS, while reducing adverse reactions usually associated with systemic TGF-b inhibition.
Company Financials
EPS
BCAX has released its 2025 Q1 earnings. EPS was reported at -0.68, versus the expected -0.4, missing expectations. The chart below visualizes how BCAX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available